Relationships among serum CA15-3 tumor marker, TNM staging, and estrogen and progesterone receptor expression in benign and malignant breast lesions

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 3, 2012, Pages 857-860

  Atoum, Manar ^a   Nimer, Nisreen ^a   Abdeldayem, Sawsan ^b   Nasr, Hamzah ^c  

^a HASHEMITE UNIVERSITY   (Jordan)

^b KING HUSSEIN MEDICAL CENTER   (Jordan)

^c Reference Medical Laboratories   (Jordan)

Author keywords

Benign lesions; Breast cancer; Healthy females; Jordan; Serum CA15 3

Indexed keywords

ESTROGEN RECEPTOR; MUCIN 1; PROGESTERONE RECEPTOR; TUMOR MARKER;

AGED; ARTICLE; BLOOD; BREAST TUMOR; CANCER STAGING; FEMALE; GENETICS; HUMAN; JORDAN; METABOLISM; MIDDLE AGED; PATHOLOGY;

AGED; BREAST NEOPLASMS; FEMALE; HUMANS; JORDAN; MIDDLE AGED; MUCIN-1; NEOPLASM STAGING; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 84871671473     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.3.857     Document Type: Article

References (36)

1. Anonymous (1996). Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol, 14, 2843-77.
2. Bensouda Y, André F, Boulet T, et al (2009). Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status. Bull Cancer, 96, 923-8
3. Berruti A, Tampellini M, Torta M, et al (1994). Prognostic value in predicting overall survival of two mucinous markers: CA15-3 and CA 125 in breast cancer patients at first relapse of disease. Eur J Cancer, 30, 2082-4
4. Brekelmans CT (2003). Risk factors and risk reduction of breast and ovarian cancer. Curr Opin Obstet Gynecol, 15, 63-8.
5. Busetto M, Vianello L, Franceschi R, Bolzan M (1995). CA 15-3 value and neoplastic disease predictivity in the follow-up for breast cancer. Tumour Biol, 16, 243-53.
6. Cengiz B, Atabekoglu C, Cetinkaya E, Cengiz SD (2003). Effect of hormone replacement therapy on serum levels of tumor markers in healthy postmenopausal women. Maturitas, 46,301-6.
7. Cheung K, Graves CRL, Robertson JFR (2000). Tumor marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev, 26,91-102.
8. Coveney EC, Geraghty JG, Sherry F, et al (1995). The clinical value of CEA and CA 15-3 in breast cancer management. Int J Biol Markers, 10, 35-41.
9. Crump C, McIntosh MW, Urban N, Anderson G, Karlan BY (2000). Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening. Cancer Epidemiol Biomarkers Prev, 9, 1107-11.
10. Dehaghani AS, Ghiam AF, Hosseini M, Mansouri S, Ghader A (2007). Factors Influencing Serum Concentration of CA125 and CA15-3 in Iranian Healthy Postmenopausal Women. Pathology Oncol Res, ?, 13360-364.
11. Duffy MJ (1999). CA 15-3 and related mucins as circulating markers in breast cancer. Ann Clin Biochem, 36, 579-86.
12. Duffy MJ (2006). Serum tumor markers in breast cancer: Are they of clinical value? Clinical Chemistry, 52, 345-51
13. Elston CW, Ellis IO, Pinder SE (1999). Pathological prognostic factors in breast cancer. Crit Rev Oncol Haematol, 31, 209-23.
14. Gang Y, Adachi I, Ohkura H, (1985). CA15-3 is present as a novel tumor marker in the sera of patients with breast cancer and other malignancies. Gan To Kagaku Ryoho, 12, 2379-86
15. Gion M, Boracchi P, Dittadi R, et al (2002) Prognostic role of serum CA15.3 in 362 node-negative breast cancers. An old player for a new game. Eur J Cancer, 38, 1181-8.
16. Hayes DF, Mesa Tejada R, Papsidero L, et al (1991). Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a Cancer and Leukemia Group B study. J Clin Oncol, 9, 1113-23.
17. Hayes DF, Zurawski VR, Kufe DW (1986). Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol, 4, 1542-50.
18. Jordan breast cancer program: http://www.jbcp.jo/node/14
19. Kikuchi K, Uematsu Y, Takada Y, et al (1987). Evaluation of tumor marker CA15-3 in breast cancer. Gan To Kagaku Ryoho, 14, 3095-100.
20. Kobayashi S, Iwase H, Karamatsu S, et al (1989). The clinical value of serum CA15-3 assay postoperatively in breast cancer patients. Jpn J Surg, 19, 278-82.
21. Kochanska Dziurowicz A, Pasich R, Stanjek A, Gawel Szostek V, T Jankowski (2000). Serum concentration of selected neoplasm markers: CA15-3, TPS and CEA in women with diagnosed breast benign disease. Ginekol Pol, 71, 1139-43
22. Lumachi F, Basso SM, Brandes AA, Pagano D, Ermani M (2004). Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer. Anticancer Res, 24, 3221-4.
23. McLaughlin R, McGrath J, Grimes H, Given HF (2000). The prognostic value of the tumor marker CA 15-3 at initial diagnosis of patients with breast cancer. Int J Biol Markers, 15, 340-2.
24. Molina R, Jo J, Zanón G, et al (1996). Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3. Br J Cancer, 74, 1126-31.
25. Molina R, Jo J, Filella X, et al (1999). C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients. Anticancer Res, 19, 2551-5.
26. Nicolini A (2000). Carpi A. Postoperative follow-up of breast cancer patients: overview of progress in the use of tumor markers. Tumor Biol, 21, 235-48.
27. Pike MC, Pearce CL, Wu AH (2004) Prevention of cancers of the breast, endometrium and ovary. Oncogene, 23, 6379-91.
28. Rymer J, Morris EP (2000). Extracts from "Clinical evidence": Menopausal symptoms. BMJ, 321, 1516-9.
29. Seregni E, Botti C, Bajetta E, et al (1999). Bombardieri E: Hormonal regulation of MUC1 expression. Int J Biol Markers, 14, 29-35.
30. Shering SG, Sherry F, McDermott EW, et al (1998). Preoperative CA15-3 concentrations predict outcome of patients with breast carcinoma. Cancer, 83, 2521-7.
31. Singletary SE, Allred C, Ashley P, et al (2002). Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol, 20, 3628-36.
32. Tampellini M, Berruti A, Gerbino A, et al (1997). Relationship between CA15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease. Br J Cancer, 75, 698-702.
33. Taylor PJ, Burchell JM, Plunkett T, et al (2002). MUC1 and the immunobiology of cancer. J Mammary Gland Biol Neoplasia, 7, 209-21.
34. Theriault RL, Hortobagyi GN, Fritsche HA, et al (1989). The role of serum CEA as a prognostic indicator in stage II and III breast cancer patients treated with adjuvant chemotherapy. Cancer, 63, 828-35.
35. Thompson JA, Grunert F, Zimmermann W (1991). Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal, 5, 344-66.
36. Thriveni K, Krishnamoorthy L, Ramaswamy G (2007). Correlation study of carcinoembryonic antigen & cancer antigen 15.3 in pretreated female breast cancer patients. Indian J Clin Biol, 22, 57-60